Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Leukemia, acute myeloid (AML), child
Stage/Subtype:  recurrent childhood acute myeloid leukemia
Country:  U.S.A.
Trial Type:  Treatment
Trial Status:  Active
Results 1-25 of 77 for your search:
Start Over
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: not specified
Sponsor: NCI, Other
Protocol IDs: 2448.00, NCI-2010-02035, P01CA018029, P30CA015704, NCT01231412
Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Phase: Phase III
Type: Treatment
Status: Active
Age: 3 to 70
Sponsor: Other
Protocol IDs: 2011-0628, NCI-2012-00038, NCT01471444
Reduced Intensity Transplant Using Extracorporeal Photopheresis
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and under
Sponsor: Other
Protocol IDs: ECP RIT, NCT00179790
Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Any age
Sponsor: NCI, Other
Protocol IDs: 2230.00, NCI-2010-00106, P01CA078902, P30CA015704, FHCRC-2230.00, IR-6771, NCT00789776
Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: SCT 0208, NCT00679536
Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 6 montha to 70
Sponsor: Other
Protocol IDs: J1055, NA_00039823, NCT01203722
Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: 2498.00, NCI-2011-03362, P01CA018029, P30CA015704, NCT01640301
Phase I/II MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 13 to 60
Sponsor: NCI, Other
Protocol IDs: BMT236, SU-09142011-8407, NCT01660607
IL-21-Expanded NK Cells for Induction of Acute Myeloid Leukemia (AML)
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 2 to 59
Sponsor: Other
Protocol IDs: 2012-0079, NCI-2014-00883, 8009, NCT01787474
Natural Killer (NK) Cells With HLA Compatible Hematopoietic Transplantation for High Risk Myeloid Malignancies
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 65 and under
Sponsor: Other
Protocol IDs: 2012-0819, RP110553-P3), NCI-2013-00993, NCT01823198
Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 30 and under
Sponsor: Other
Protocol IDs: NYMC 542, L 10, 819, NCT01842672
AC220 With 5-Aza or Low Dose Cytarabine
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 2012-1047, NCI-2013-02274, P50 CA100632, NCT01892371
Haplo-identical SCT for HR Hematologic Malignancies w/Post-Transplant In-Vivo T-cell Depletion
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: SCT 0813 Haplo, NCT02053545
Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 24 and under
Sponsor: Other
Protocol IDs: SELHEM, NCI-2014-01704, NCT02212561
PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 3 to 30
Sponsor: NCI
Protocol IDs: 150093, 15-C-0093, NCT02390752
Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases
Phase: Phase II
Type: Treatment
Status: Active
Age: 45 and under
Sponsor: Other
Protocol IDs: 2005LS043, UMN-MT2005-10, UMN-0507M71475, UMN-2005LS043, UMN-BMT-MT2005-10, NCT00309842
Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy
Phase: Phase II
Type: Treatment
Status: Active
Age: Under 70
Sponsor: Other
Protocol IDs: 2001LS058, UMN-MT2001-10, 0108M06725, UMN-2001LS058, NCT00303719
Immunoablative Mini Transplant (Hematopoietic Peripheral Blood Stem Cell Transplant [HPBSC])
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and under
Sponsor: Other
Protocol IDs: BMT 0300 Mini, NCT00179764
Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant
Phase: Phase II
Type: Treatment
Status: Active
Age: Under 70
Sponsor: Other
Protocol IDs: 2005LS036, UMN-MT-2005-02, UMN-0507M70121, UMN-2005LS036, NCT00305682
Combination Chemotherapy Followed By Donor Umbilical Cord Blood Transplant in Treating Infants With High-Risk Acute Leukemia or Myelodysplastic Syndromes
Phase: Phase II
Type: Treatment
Status: Active
Age: 2 and under at diagnosis
Sponsor: Other
Protocol IDs: 2005LS075, UMN-MT2005-25, UMN-0511M77206, UMN-2005LS075, NCT00357565
Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies
Phase: Phase II
Type: Treatment
Status: Active
Age: 2 to 21
Sponsor: Other
Protocol IDs: HIFLEX, NCI-2011-03670, NCT00566696
CHP 834 Unrelated and Partially Matched Related Donor Peripheral Stem Cell Transportation for T and B Cell Depletion
Phase: Phase II
Type: Treatment
Status: Active
Age: 22 and under
Sponsor: Other
Protocol IDs: 2005-3-4222, NCT00579124
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: Any age
Sponsor: NCI, Other
Protocol IDs: 2239.00, NCI-2009-01551, 2239, P30CA015704, FHCRC-2239.00, 6722, FHCRC-IR-6722, NCT00723099
Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant
Phase: Phase II
Type: Treatment
Status: Active
Age: Under 65
Sponsor: NCI, Other
Protocol IDs: 2275.00, NCI-2010-00299, P30CA015704, FHCRC-2275.00, IR-6800, NCT00796068
Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies
Phase: Phase II
Type: Treatment
Status: Active
Age: Under 60
Sponsor: Other
Protocol IDs: 2008-0363, NCI-2012-01630, NCT00857389
Start Over